G
Gilead Sciences, Inc. (GILD)
NMS – Real vaqt narxi. Valyuta: USD
134.94
+1.42 (1.06%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
134.94
+1.42 (1.06%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Gilead Sciences, Inc., biofarmatsevtika kompaniyasi, Qo'shma Shtatlar, Yevropa va xalqaro miqyosda tibbiy ehtiyojlari qondirilmagan sohalarda dori-darmonlarni kashf etadi, ishlab chiqadi va tijoratlashtiradi. Kompaniya bemorlarda OIV-1 infektsiyasini davolash uchun Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza va Yeztugo taqdim etadi. Shuningdek, u surunkali gepatit C virusi, birlamchi o't xolangi va surunkali gepatit B virusini davolash uchun Epclusa, Livdelzi va Vemlidy; kattalar bemorlarni davolash uchun T-hujayrali terapiya bo'lgan Tecartus; tomir ichiga yuborish uchun in'ektsiya bo'lgan Trodelvy; va kattalar bemorlarni davolash uchun CAR T-hujayrali terapiya bo'lgan tomir ichiga yuborish uchun suspenziya bo'lgan Yescarta taqdim etadi. Shuningdek, u jiddiy invaziv qo'ziqorin infektsiyalarini davolash uchun AmBisome; va COVID-19 ni davolash uchun Veklury taqdim etadi. Qo'shimcha ravishda, kompaniya saraton va boshqa davolash mumkin bo'lmagan kasalliklarga chalingan bemorlar uchun turli immunoterapiyalarni ishlab chiqish bilan shug'ullanadi. Kompaniya Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; va Assembly Biosciences, Inc. bilan hamkorlik shartnomalariga ega. Shuningdek, u yangi ikkilamchi o'simta bilan bog'liq antigenlarga (TAA) yo'naltirilgan trispesifik antitelarni kashf qilish uchun Merus N.V. bilan tadqiqot hamkorligi, opsion va litsenziyalash shartnomasiga ega. Kompaniya kichik molekulali terapiyalarni kashf qilish va ishlab chiqish uchun Terray Therapeutics, Inc. bilan; va kichik molekulali og'iz orqali yuboriladigan STAT6 dasturini ishlab chiqish, ishlab chiqarish va tijoratlashtirish uchun LEO Pharma bilan hamkorlik qiladi. Kompaniya 1987 yilda tashkil etilgan va shtab-kvartirasi Kaliforniyaning Foster City shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Dietmar P. Berger M.D., Ph.D. | Chief Medical Officer |
| Dr. Flavius Martin M.D. | Executive Vice President of Research |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation & Portfolio |
| Mr. Andrew D. Dickinson | Chief Financial Officer |
| Mr. Daniel P. O'Day | Chairman & CEO |
| Ms. Erin E. Burkhart | Senior VP, Controller & Principal Accounting Officer |
| Ms. Jacquie Ross C.F.A. | Senior Vice President of Treasury & Investor Relations |
| Ms. Johanna Mercier | Chief Commercial & Corporate Affairs Officer |
| Ms. Jyoti K. Mehra | Executive Vice President of Human Resources |
| Ms. Keeley M. Cain Wettan | Executive VP and General Counsel of Legal & Compliance |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | gild-20260331.htm |
| 2026-05-04 | 8-K | gild-20260430.htm |
| 2026-04-28 | SC TO-T/A | tm2612748d3_sctota.htm |
| 2026-04-28 | 8-K | tm2612748d1_8k.htm |
| 2026-04-17 | SC TO-T/A | tm2612074d1_sctota.htm |
| 2026-04-01 | SC TO-T/A | tm2610852d1_sctota.htm |
| 2026-03-20 | DEF 14A | gild2026_courtesy-pdf.pdf |
| 2026-02-24 | 10-K | gild-20251231.htm |
| 2026-02-23 | SC TO-C | tm267044d1_8k.htm |
| 2026-02-23 | 8-K | tm267044d1_8k.htm |